Viking Therapeutics shares are trading higher after the company announced the advancement of VK2735 to Phase 3.
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics shares are trading higher after the company announced the advancement of VK2735 to Phase 3.
July 25, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics shares are trading higher following the announcement that VK2735 has advanced to Phase 3 trials.
The advancement of VK2735 to Phase 3 is a significant milestone for Viking Therapeutics, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100